Sign inJoin waitlistJoin the waitlist

Lauren Dockery

Assistant Professor · University of Oklahoma College of Medicine

Credentials: · · · · · · ·

History

University of Oklahoma College of Medicine
Present

Gynecologic Oncology
University of Oklahoma Health Sciences Center
2019–2022
Obstetrics and Gynecology
Tufts Medical Center
2015–2019
University of Oklahoma Health Sciences
Virginia Commonwealth University School of Medicine
2008–2012

Research

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Review · OncoTargets and Therapy · 2017 · First of 3 authors · 53 citations
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
Gynecologic Oncology · 2017 · First of 4 authors · Corresponding · 37 citations
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Clinical Cancer Research · 2024 · 26 citations

Kathleen Moore
13 papers
Robert Mannel
6 papers
Theresa Thai
5 papers
Debra Richardson
4 papers
Camille Jackson
3 papers · 1 as a fellow
Laura Holman
3 papers · 1 as a resident
Lisa Landrum
3 papers
AT
Ahmad Tarhini
2 papers
Aliza Leiser
2 papers
Andrew Polio
2 papers · 2 as a fellow
Bradley Corr
2 papers
Casey Cosgrove
2 papers

Grants

Oklahoma Center of Medical Imaging for Translational Cancer Research
National Institute of General Medical Sciences · P20
Project lead · $521.7K · University of Oklahoma
2022–2026

Clinical trials

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Principal investigator · Terminated · Phase 2
University of Oklahoma
2023–2025
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Site PI · Recruiting · Phase 2
Aadi Bioscience, Inc.
2023–2027
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027